Investigations
Y-mAbs Therapeutics, Inc.
Y-mAbs Therapeutics, Inc. (YMAB) Misrepresented the Viability and Efficacy of its Lead Drug Candidate
January 20, 2023
THE NEWSROOM
Search
Categories
Archives
Investment Monitoring From Robbins LLP
To ensure your financial investments are being managed honestly, enroll in Stock Watch, our free investment monitoring service for individual and institutional investors.
Investigations
Latch, Inc.
Latch, Inc. (LTCH) f/k/a TS Innovation Acquisitions Corp. (TSIA) Issued a False and Misleading Registration Statement in Connection with its Merger
January 13, 2023
Robbins LLP News
The U.S. Securities and Exchange Commission is Busy at Work
The SEC is Making Changes in 2023
January 11, 2023
Investigations
Enovix Corporation
Enovix Corporation (ENVX) Misled Investors Regarding its Ability for Production and Profitability
January 9, 2023
Investigations
ForgeRock, Inc.
Robbins LLP is Investigating the Acquisition of ForgeRock, Inc. by Thoma Bravo
January 6, 2023
Investigations
BioLineRx Ltd.
BioLineRx Ltd. (BLRX) Misrepresented its Financial Fortitude and Ability to Bring its Drug to Market
January 6, 2023
Investigations
Avaya Holdings Corp.
Avaya Holdings Corp. (AVYA) Failed to Disclose Deficient Internal Control Over Financial Reporting
January 5, 2023
Investigations
Gaotu Techedu, Inc. f/k/a GSX Techedu, Inc.
Gaotu Techedu, Inc. (GOTU) Failed to Disclose the Impact of China’s Ban on For-Profit Tutoring on Its Business Prospects
January 3, 2023
Investigations
Daktronics, Inc.
Daktronics, Inc. (DAKT) Unable to Timely File SEC Reports and Questions its Ability to Continue as a Going Concern
December 28, 2022
Protect your